Abstract 1535P
Background
Ramucirumab (Ram) combined with docetaxel is an approved 2nd-line treatment in patients (pts) with squamous cell carcinoma (SCC) of the lung (REVEL study) and with paclitaxel for esophagogastric adenocarcinoma (RAINBOW study). In SCC of the oesophagus, nivolumab is currently the only evidence-based 2nd-line treatment option. This study evaluates the safety and efficacy of Ram plus paclitaxel.
Methods
This prospective, randomized, open-label, multicentre, phase II trial evaluated paclitaxel plus Ram (Ram 8 mg/kg d1, 15 and paclitaxel 80 mg/m2 d1, 8, 15) Arm A vs. paclitaxel alone (80 mg/m2 d1, 8, 15) Arm B, both q4w. Primary endpoint was overall survival rate at 6 months (mos) (OS@6), main secondary endpoints were OS, PFS, objective response rate (ORR) and safety.
Results
From 3/2019 to 4/2021, 21/186 planned pts were treated within the study protocol (Arm A 11 pts; Arm B 10 pts) in 9 German centres. Due to slow accrual, the study was terminated prematurely. Median age was 63y, 71% were male and 86% had relevant concomitant disease. Pts received a median of 9 and 10 cycles in Arms A and B, respectively. Median follow-up was 9 mos (0.7 – 32.4 mos). OS@6 in Arm A was 73% for Ram/paclitaxel and 50% for paclitaxel. However, the study design did not allow for statistical comparison of the arms. ORR (CR+PR 18% vs. 20%) and DCR (CR+PR+SD 55% vs. 60%) were in the same range, as well as median PFS (3.8 vs. 3.5 mos) and OS (12.1 vs. 9.2 mos) for Arms A and B, respectively. The most common treatment related adverse events (AEs) in Arm A were leucopoenia (55%), fatigue (27%) and peripheral sensory neuropathy (18%). Treatment related AEs ≥ grade 3 occurred in 27% in Arm A and 50% in Arm B. Serious AEs (SAEs) occurred in 36% and 50% in Arms A and B, respectively.
Conclusions
Ram and Paclitaxel shows an acceptable tolerability and numerically improved OS@6. Due to the small number of pts the current trial must be considered exploratory, and more data are needed in this indication.
Clinical trial identification
NCT03762564.
Editorial acknowledgement
Legal entity responsible for the study
Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest.
Funding
Lilly Deutschland GmbH.
Disclosure
T.O. Goetze: Other, Advisory Role: Lilly, MSD Oncology, Bayer, Servier, Roche, Novartis, Incyte, Foundation Medicine, Bristol Myers Squibb; Other, Speaker’s Bureau: Lilly; Financial Interests, Research Funding: Deutsche Forschungsgemeinschaft, Gemeinsamer Bundesausschuss, Deutsche Krebshilfe, Lilly, AstraZeneca, Incyte. T.J. Ettrich: Other, Advisory Role: Eisai, MSD Oncology, Bayer, Roche, Sanofi, Bristol Myers Squibb, Incyte, AstraZeneca, Merck, Pierre Fabre, Servier, Lilly, Ipsen, BMS GmbH & Co. KG, Daiichi Sankyo Europe GmbH; Financial Interests, Other, Travel, Accommodations, Expenses: Ipsen; Financial Interests, Research Funding: Baxalta/Shire. H. Schmalenberg: Other, Advisory Role: Lilly, Novartis, BMS GmbH & Co. KG, MSD, Merck. R.J.C. Mahlberg: Other, Advisory Role: AstraZeneca. G. Hapke: Financial Interests, Research Funding: MSD, Bristol Myers Squibb, Gilead Sciences, BioNTech. P.C. Thuss-Patience: Other, Advisory Role: Bristol Myers Squibb, Merck, Lilly, Novartis, Pfizer, Roche, AstraZeneca, Daiichi Sankyo, Astellas Pharma, MSD, Servier; Financial Interests, Research Funding: Merck/Pfizer. S. Al-Batran: Other, Advisory Role: Lilly, Bristol Myers Squibb, Merck Sharp & Dohme, MacroGenics, AstraZeneca, Daiichi Sankyo; Other, Speaker’s Bureau: Lilly, AIO GmbH, Bristol Myers Squibb, MCI Group; Financial Interests, Stocks or ownership: Institut für Klinische Krebsforschung GmbH, Immutep; Financial Interests, Research Funding: Celgene, Lilly, Medac, Hospira, Sanofi, German Cancer Aid, German Research Foundation, Federal Ministry of Education and Research, Roche, Vifor Pharma, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21